Fat Distribution and Glucose Metabolism in Williams Syndrome

Completed

• Conditions: Williams Syndrome

• Registration Number: NCT01864304
• Lead Sponsor: Massachusetts General Hospital

Brief Summary

Williams Syndrome (WS) is a genetic syndrome with features that may include vascular stenoses, neuro-developmental changes, and a variety of endocrine and metabolic abnormalities, including impaired glucose metabolism and abnormal body composition. Approximately 75% of adults with WS have impaired glucose tolerance or diabetes on oral glucose tolerance testing (OGTT). In addition, clinical observations and preliminary data suggest increased overall body fat in these individuals, as well as a relative increase in fat deposition in the lower extremities. However, glucose and lipid metabolism in WS remain incompletely characterized. The purpose of the current study is to carefully describe glucose metabolism and lipid parameters in people with WS.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-05-10
• Study First Submitted QC: 2013-05-24
• Study First Posted: 2013-05-29
• Study Start: 2013-12
• Primary Completion: 2016-02
• Study Completion: 2016-02
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-06
• Last Update Posted: 2017-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
2-hour glucose	Baseline	Blood glucose concentration two hours after drinking a sugary drink (oral glucose tolerance test)

Secondary Outcome Measures

Name	Time	Method
Percent body fat	Baseline	percent body fat as measured by whole body dual-energy xray absorptiometry (DXA) scanning
Low-density lipoprotein cholesterol (LDL)	Baseline

Trial Locations

Locations (1)

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States